Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma

Clinical Nuclear Medicine

Volumn 37, Issue 8, 2012, Pages 759-762

  Lu, Yang ^a,b   Fleming, Stephen E ^a   Fields, Ryan C ^a   Coit, Daniel G ^a   Carrasquillo, Jorge A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

FDG PET CT; Merkel cell carcinoma; pentetreotide; somatostatin analog scintigraphy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PENTETREOTIDE; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MERKEL CELL TUMOR; METASTASIS; TUMOR BIOPSY; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SOMATOSTATIN; WHOLE BODY IMAGING;

EID: 84863867007     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31825ae8e7     Document Type: Article

References (23)

1. Medina-Franco H, Urist MM, Fiveash J, et al. Multimodality treatment of merkel cell carcinoma: case series and literature reviewof 1024 cases. Ann Surg Oncol. 2001;8:204-208. (Pubitemid 32294799)
2. Kaae J, Hansen AV, Biggar RJ, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010;102:793-801.
3. Fields RC, Busam KJ, Chou JF, et al. Five hundred patients with merkel cell carcinoma evaluated at a single institution. Ann Surg. 2011;254:465-475.
4. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J ClinOncol. 2005;23:2300-2309. (Pubitemid 46218722)
5. Fields RC, Busam KJ, Chou JF, et al. Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institution. Ann Surg Oncol. 2011;18:2529-2537.
6. Zager JS, Brodsky S, Berman CG. Imaging of merkel cell carcinoma. Curr Probl Cancer. 2010;34:65-76.
7. Concannon R, Larcos GS, Veness M. The impact of (18)F-FDG PET/CT scanning for staging and management of merkel cell carcinoma: results from westmead hospital, sydney, australia. J Am Acad Dermatol. 2010;62:76-84.
8. 18FDG PET in neuroendocrineYmerkel cell carcinoma. Oncol Rep. 2006;16:347-352.
9. Durani BK, Klein A, Henze M, et al. Somatostatin analogue scintigraphy in merkel cell tumours. Br J Dermatol. 2003;148:1135-1140. (Pubitemid 36819211)
10. Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, et al. Indium-111 octreotide scintigraphy of merkel cell carcinomas and their metastases. Ann Oncol. 2001; 12:807-811. (Pubitemid 32655090)
11. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89:1-4. (Pubitemid 40075960)
12. Young JL, Ward KC, Ries LAG. Cancer of rare sites. In: Ries LAG, Young JL, Keel GE, et al, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988Y2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute; 2007:251-261.
13. Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol. 2010;37:662-679.
14. Eftekhari F, Wallace S, Silva EG, et al. Merkel cell carcinoma of the skin: Imaging and clinical features in 93 cases. Br J Radiol. 1996;69:226-233. (Pubitemid 26093184)
15. Gupta SG,Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with merkel cell carcinoma-the Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006;142:685-690.
16. Anderson SE, Beer KT, Banic A, et al. MRI of merkel cell carcinoma: histologic correlation and review of the literature. AJR Am J Roentgenol. 2005;185: 1441-1448.
17. Kamo R, Kumei A, Ueoku S, et al. Importance of sentinel lymph node biopsy in merkel cell carcinoma. J Dermatol. 2010;37:1068-1070.
18. Kwekkeboom DJ, Hoff AM, Lamberts SW, et al. Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of merkel cell tumors and their metastases. Arch Dermatol. 1992;128:818-821.
19. 111In-DTPA-octreotide (OctreoScan). Mol Imaging Biol. 2011;13:583-593.
20. Scanga DR, Martin WH, Delbeke D. Value of fdg pet imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med. 2004;29:86-90. (Pubitemid 38240735)
21. Grewal RK, Pandit-Taskar N, Gonen M, et al. FDG PET for evaluation of merkel cell carcinoma. J Nucl Med. 2005;46:137.
22. Iagaru A, Quon A, McDougall IR, et al. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[F-18]fluoro-D-glucose PET/CT? Mol Imaging Biol. 2006;8: 212-217.
23. Peloschek P, Novotny C, Mueller-Mang C, et al. Diagnostic imaging in merkel cell carcinoma: Lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol. 2010;73:317-323.